Douglas Kirk Ways - 11 Dec 2025 Form 4 Insider Report for SPRUCE BIOSCIENCES, INC. (SPRB)

Reporting relationship: Interim Chief Medical Officer, Director
Issuer ticker: SPRB
Reported as of: 11 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jan 2026, 16:04:35 UTC
Prior SEC filing: 24 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Samir Gharib, Attorney-in-Fact

Key filing fact

Douglas Kirk Ways filed Form 4 for SPRUCE BIOSCIENCES, INC. (SPRB) on 21 Jan 2026.

Key facts

This page summarizes Douglas Kirk Ways's Form 4 filing for SPRUCE BIOSCIENCES, INC. (SPRB).
7 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 21 Jan 2026, 16:04.

Change

Previous filing in this sequence was filed on 24 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001869391 Primary reporting owner

Ways Douglas Kirk

Relationship: Interim Chief Medical Officer, Director
Address: C/O SPRUCE BIOSCIENCES, INC., 611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Signature: /s/ Samir Gharib, Attorney-in-Fact
Signature date: 21 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SPRB transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +1,250
Change %
Price: $0.000000
Shares after: 1,250
Date: 11 Dec 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SPRB transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +5,000
Change %
Price: $0.000000
Shares after: 5,000
Date: 11 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,000
Exercise price: $0.000000
Footnotes: F1, F2

SPRB transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -1,250
Change %: -25%
Price: $0.000000
Shares after: 3,750
Date: 11 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,250
Exercise price: $0.000000
Footnotes: F1, F2

SPRB transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +266
Change %
Price
Shares after: 266
Date: 11 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 266
Exercise price: $104.13
Footnotes: F3, F4, F5, F6

SPRB transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -266
Change %: -100%
Price
Shares after: 0
Date: 11 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 266
Exercise price: $791.25
Footnotes: F3, F4, F5, F6

SPRB transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +400
Change %
Price
Shares after: 400
Date: 11 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 400
Exercise price: $104.13
Footnotes: F3, F4, F5, F6

SPRB transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -400
Change %: -100%
Price
Shares after: 0
Date: 11 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 400
Exercise price: $169.50
Footnotes: F3, F4, F5, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

25% of the total number of restricted stock units ("RSUs") vested on grant. 25% of the total number of RSUs will vest on December 15, 2026, December 15, 2027 and December 15, 2028, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan) as of each such vesting date.

Footnote F2

Each RSU represents a contingent right to receive one share of common stock of the Issuer.

Footnote F3

Effective August 4, 2025, the Issuer effected a reverse stock split (the "Reverse Split") whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock. In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five.

Footnote F4

The shares subject to the option are fully vested and exercisable.

Footnote F5

The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date.

Footnote F6

Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options.